The tumor necrosis factor receptor (TNFR)-associated factor (TRAF) family of six adaptor proteins (TRAF1-6) links the TNFR superfamily to the nuclear factor kappa B (NF-jB) and activator protein-1 (AP-1) transcriptional activators. Unlike other TRAFs, TRAF6 is also involved in Toll-like/interleukin (IL)-1 receptor (TIR) signal transduction. Thus, inhibition of TRAF6 function could interrupt both CD40 (TNFR family) and IL-1 growth signals, pathways critical to myeloma proliferation. To block TRAF6-mediated IL-1 signaling, we constructed small interfering RNA (siRNA) against TRAF6. We found that siRNA targeting the TRAF6 C-terminal (siTRAF6C) receptor interaction domain specifically reduced only TRAF6 protein expression, without affecting TRAF2 or 5 levels, and substantially interfered with IL-1-induced NF-jB and c-Jun/AP-1 activation. Inhibition by siTRAF6C was concentration-dependent. SiTRAF6C also significantly reduced myeloma proliferation and enhanced apoptosis in a similar dose-dependent fashion in vitro. More importantly, marked siTRAF6C growth inhibition was detected in vivo when these cells were implanted into the bone marrow of irradiated normal mice. In contrast, introduction of siRNA derived from the TRAF6 Zn-finger domain or an irrelevant siRNA construct failed to alter cell growth or cell death. These studies suggest that
Introduction
Multiple myeloma (MM) arises from an accumulation of malignant plasma B cells in the bone marrow (BM). Dysregulated nuclear factor kappa B (NF-kB) and mitogen-activated protein kinase (MAPK) activation results in prolonged survival of the myeloma cells and has been associated with increased tumor cell survival and resistance to chemotherapy (Bharti et al., 2004; Chatterjee et al., 2004; Nakanishi and Toi, 2005; Sanda et al., 2005) . Tumor necrosis-associated factors (TRAFs) form a family of cytoplasmic adaptor proteins that mediate intracellular signal transduction of receptors of the tumor necrosis factor and toll-like receptor (TLR)/interleukin (IL)-1 (TIR) superfamilies (Cao et al., 1999; Inoue et al., 2000) . The TRAF proteins are composed primarily of four domains, an amino-terminal RING-finger, multiple zinc-finger repeats (TRAFZnfinger) involved in effector function, and the N (TRAFN) and C-terminal (TRAFC) domains required for TRAF trimerization (TRAFN) and receptor selectivity (TRAFC, Cheng et al., 1995; Takeuchi et al., 1996; Inoue et al., 2000) . Of the six TRAF members identified, TRAF6 has the most divergent TRAFC domain (Inoue et al., 2000) . Furthermore, TRAF6 is the only member involved in the signaling of the TIR family, and thus, the only member that participates in signal transduction of both the tumor necrosis factor receptor (TNFR) and TIR superfamilies (Cao et al., 1996; Lomaga et al., 1999; Naito et al., 1999; Aderem and Ulevitch, 2000; Chung et al., 2002) .
Following IL-1 stimulation, the adaptor complex MyD88 and Tollip are recruited to the IL-1R complex and activate the serine/threonine IL-1R-associated kinases (IRAKs). Almost simultaneously, hyperphosphorylated IRAK incorporates TRAF6 into the complex followed by release from the receptor and assembly into new complexes containing TAK1, TAB1 and TAB2. In the cytoplasm, the TRAF6 RING finger ubiquitinates IkB, targeting it for proteasomal degradation and releasing activated NF-kB. Activation of the TRAF6 complex also results in signaling by the MAPK, including c-Jun NH 2 -terminal kinase (JNK), leading to the induction of activator protein-1 (AP-1) and transcription of genes promoting proliferation (Eferl and Wagner, 2003) .
Previously, we showed that inhibition of IkBa degradation by a proteasome inhibitor could modulate NF-kB activity and greatly increase sensitivity to chemotherapy in chemo-resistant myeloma cells without damaging normal BM cells (Berenson et al., 2001; Ma et al., 2003) . Therefore, as an extension of our studies, we investigated the potential of using small interfering RNA (siRNA) to inhibit the TRAF6-mediated activation of NF-kB. In this study, we constructed two different siRNAs from the TRAFC and Zn-finger domains of TRAF6 and introduced them into myeloma cells to block TRAF6 gene expression. Moreover, we determined the effect of silencing TRAF6 mRNA in MM cells on NF-kB and AP-1 activities, cell signaling and tumor cell proliferation and apoptosis.
Results
TRAF6C siRNA interferes with IL-1-induced NF-kB activation through specific inhibition of TRAF6 To interrupt NF-kB activation by IL-1, siRNA to the Zn-finger and TRAFC domains of TRAF6 mRNA were constructed. To confirm that the TRAF6C siRNA specifically and efficiently inhibited TRAF6 expression, the myeloma cell line RPMI 8226 was transduced with a green fluorescent protein (GFP) expression construct and GFP þ cells sorted by fluorescence-activated cell sorting (FACS). Stable GFP þ RPMI 8226 transductants (8226/GFP) were transfected with varying concentrations of TRAF6C siRNA and the cells analysed for TRAF2, TRAF5 and TRAF6 protein expression by Western blot. TRAF6C siRNA markedly reduced TRAF6 protein in a concentration-dependent fashion (Figure 1 ). In contrast, even at the highest dose, TRAF6 siRNA did not alter TRAF2 or TRAF5 protein levels, demonstrating that this construct is specific for TRAF6. To test whether inhibition of TRAF6 expression with TRAF6C siRNA would abolish NF-kB and/or AP-1 activation in response to IL-1 stimulation, stable 8226/ GFP transductants were transfected with 50 nM control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) siRNA, then stimulated with IL-1b for various times and the cells assayed for induction of the NF-kB and AP-1 pathways by Western blot for total protein and phosphorylated IkBa (S32/36) and NF-kB (S536, NFkB pathways), and SEK1 (specific protein kinase SAPK/ ERK kinase)/MKK4 (S257/T61) and c-Jun (S63, AP-1 pathway, Figure 2 ). 8226/GFP carrying siGAPDH cells responded with maximal phosphorylation when stimulated with IL-1b for 30 min (Figure 2) . TRAF6C siRNA was then introduced into these cells by transient transfection at several concentrations, the cells stimulated with IL-1b for 30 min, and NF-kB and AP-1 activation determined as outlined above. Si TRAF6C reduced IkBa and NF-kB serine phosphorylation (Figure 2 ). In addition, SEK1/MKK4 and downstream c-Jun activation were similarly inhibited by this siRNA (Figure 2 ). Thus, siTRAF6C efficiently interfered with the phosphorylation cascade that transduced signals from the IL-1 surface receptor to the nucleus. siTRAF6 inhibits myeloma proliferation and enhances apoptosis TRAF6 siRNA inhibited IL-1b induction of NF-kB as well as AP-1 and NF-kB-regulated transcriptional activation. To determine whether TRAF6 inhibition was sufficient to reduce the proliferation of myeloma cells, we transfected 8226/GFP myeloma cells with siRNA to the TRAF6C and Zn-finger domain (TRAF6Zn-finger) and with a control siRNA construct (siGAPDH). Proliferation of the GFP þ -transfected cells was assessed by fluorescence microscopy and 3-[4,5] dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay. The introduction of TRAF6C siRNA markedly reduced the number of MM cells in a dosedependent fashion (Figure 3 ), whereas neither siTRAF6Zn-finger nor siGAPDH had an effect. To quantify the growth inhibition, these cells were also analysed with an MTT assay ( Figure 4a ). Even at the highest concentration (100 nM), neither siTRAF6Zn-finger nor siGAPDH had a noticeable effect on myeloma proliferation. In marked contrast, TRAF6C significantly inhibited MM proliferation at even half of this concentration (50 nM, Po0.01, Figure 4a ). At the highest concentration (100 nM), further growth inhibition was observed (Po0.01, Figure 4a ). We extended these results to cells isolated from the BM of myeloma patients. Bone marrow mononuclear cells (BMMCs) containing >90% malignant cells were isolated from two separate patients and transfected with siTRAF6C TRAF6C siRNA inhibits myeloma cell growth H Chen et al or siGAPDH, and the proliferation of the transfected cells assayed by MTT as before. Once again, siTRAF6C significantly inhibited MM cell growth relative to the control siRNA construct (Po0.05, Figure 4b ), confirming the results obtained with the RPMI 8226 myeloma cell line. To investigate whether growth inhibition was caused by an increase in apoptosis, 8226/GFP cells transduced with TRAF6C, TRAFZn-finger or GAPDH siRNA were stained with Annexin V and propidium iodide (PPI) and analysed by flow cytometry. TRAF6C siRNA, but not siTRAFZn-finger or siGAPDH, significantly increased apoptosis in these cells in a dose-dependent fashion (Po0.01, Figure 5a ). When introduced into the BMMCs of myeloma patients, siTRAF6C similarly enhanced apoptosis relative to cells carrying the control siRNA (siGAPDH, Po0.02, Figure 5b ).
TRAF6C siRNA efficiently reduces MM cell proliferation in vivo SiTRAF6C efficiently inhibited myeloma proliferation and induced apoptosis in MM cells in vitro. These experiments, however, were performed in the absence of the BM microenvironment, known to rescue MM cells from cell death and contribute to the growth of the malignant cells (Pagnucco et al., 2004; Yaccoby et al., 2004; Vincent and Mechti, 2005) . To assess the ability of TRAF6C siRNA to interfere with the growth of MM cells within the protective BM microenvironment, 8226/ GFP myeloma cells were transfected with siTRAF6C or siGAPDH and injected into the femoral BM of irradiated mice. After 1 week, MM cells were recovered and the GFP þ cells counted by flow cytometry. 8226/ GFP cells transfected with siGAPDH cells proliferated moderately within the BMs of these mice ( Figure 6 ). When this MM cell line was transfected with si-TRAF6C, however, GFP þ cell counts were significantly reduced to less than one-half the number of GFP þ cells recovered from mice transplanted with cells transfected with siGAPDH (Po0.05, Figure 6 ). Thus, TRAF6 interference with TRAF6C siRNA is sufficient for substantial reduction of the myeloma tumor load in this in vivo model. Figure 2 TRAF6C siRNA inhibits IL-1-b-induced phosphorylation of IkB, NF-kB, SEK1 (specific protein kinase SAPK/ERK kinase)/MKK4, and cJun. Left: 8226/GFP stable transductants were transfected with control GAPH siRNA and stimulated with 20 ng/ml IL-1b for varying times. IkB, NF-kB, SEK1/MKK4 and cJun were maximally phosphorylated at 30 min. Right: multiple myeloma cells pre-treated with varying concentrations of TRAF6 siRNA prior 30 min stimulation with 20 ng/ml IL-1b. Western blots using anti-phospho-IkB, NF-kB, SEK1/MKK4, and cJun demonstrated that 100 nM siTRAF6C inhibited IL-1b activation of these signaling proteins without altering the expression levels of these proteins.
TRAF6C siRNA inhibits myeloma cell growth H Chen et al of genes involved in tumor cell proliferation, survival and chemoresistance (Berenson et al., 2001 (Berenson et al., , 2002 Ma et al., 2003; Sanda et al., 2005) . We (Ma et al., 2003) and others have reported previously that NF-kB activity was elevated in both MM cell lines (Sanda et al., 2005) and fresh BMMCs from MM patients with a high proportion of tumor (>90%) when compared with normal BMMCs (Berenson et al., 2001) . TRAF6 is critical to the activation of NF-kB and JNK in response to IL-1 stimulation (Armstrong et al., 2002; Sinha et al., 2002; Ye et al., 2002) ; thus, TRAF6 may be an important target for inducing MM cell death. To specifically inhibit TRAF6 expression, we designed siRNA to the TRAF6 Zn-finger domain, necessary for full JNK activation (Kobayashi et al., 2001) and to the TRAF6C domain, required for receptor binding. Introduction of 50 nM siTRAF6C into the RPMI 8226 myeloma cell line decreased TRAF6 protein expression. In contrast, even at a higher concentration (100 nM), neither TRAF2 nor TRAF5 levels were reduced. When these cells were stimulated with IL-1b, siTRAF6C interference decreased the activation of the NF-kB and JNK-signaling pathways as detected by Western blot for phospho-IKK, NF-kB, SEK1/MKK4 and c-Jun. To determine whether this interference with NF-kB and JNK signaling by siTRAF6C could inhibit the proliferation of myeloma cells, we transfected si-TRAF6C, siTRAF6Zn-finger and siGAPDH into RPMI 8226 cells stably transduced with GFP and measured cell growth with fluorescence microscopy and MTT assay. TRAF6C siRNA significantly inhibited proliferation and this growth inhibition was dependent on the concentration of siTRAF6C (decreased by 40% at 50 nM and by 60% at 100 nM). In contrast, the growth of MM cells transfected with a siRNA construct targeted against a different region of the TRAF6 gene (siTRAF6Zn-finger) was essentially equal to that of cells carrying a negative control siRNA (siGAPDH). Importantly, when these experiments were repeated in tumor cells from MM patients, we detected comparable inhibition (decreased by 40-50% at 100 nM). To investigate whether this effect on MM cell growth was caused by siTRAF6C-induced cytotoxicity, we measured apoptosis by Annexin V/PPI staining and flow cytometry. When 100 nM of siTRAF6C was introduced into the MM cell line or malignant plasma cells from myeloma patients, apoptosis was increased by more than twofold when compared to cells transfected with siGAPDH. Injection of 8226/GFP cells transfected with siGAPDH into the BM of irradiated mice resulted in an increase in the number of GFP þ cells within 1 week. In marked contrast, when 8226/GFP cells carrying TRAF6C siRNA were similarly injected into murine BM, the cell number significantly decreased to approximately one-half the number of implanted cells. Therefore, we have demonstrated that TRAF6 may be a new target for the treatment of myeloma and that silencing this factor could be an important strategy in the development of gene therapy for myeloma. Figure 3 Concentration-dependent inhibition of multiple myeloma cell proliferation by TRAF6C small interfering RNA. SiTRAF6C inhibited 8226/GFP proliferation in a concentration dependent fashion. In contrast, neither siTRAF6Zn-finger nor the siGAPDH negative control affected cell growth as measured by fluorescence microscopy for GFP þ cells.
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Our in vitro studies focused on inhibiting TRAF6-mediated signaling through the IL-1 receptor. TRAF6, however, also relays signals by TNFR family members, including CD40 and RANK. CD40 is highly expressed by myeloma cells and CD40 stimulation can enhance MM proliferation (Tai et al., 2005) , whereas interference with CD40L-CD40 signaling with an antagonistic monoclonal antibody can inhibit Akt, MAPK and NF-kB activation, MM cellular proliferation, cytokine secretion and adherence to BM stromal cells, and induce MM cell death (Tai et al., 2005) . CD40 stimulation of NF-kB in myeloma cells requires TRAF6 (Teoh et al., 2000) . Moreover, the efficacy of some anti-myeloma therapies has been attributed to modulation of CD40 expression (Corso et al., 2005) . Interfering with TRAF6 expression using TRAF6C siRNA should also inhibit CD40-mediated cell signaling in a manner similar to the inhibition of IL-1 stimulation that we have demonstrated in this study.
Bone destruction is a hallmark of myeloma and stimulation of osteoclasts via RANK-RANKL interactions increases bone resorption; TRAF6 is also a critical mediator of RANK signal transduction. TRAF6-deficient mice are defective in osteoclastogenesis (Naito et al., 1999) . Osteoclastogenesis can also be inhibited by interferon-g-induced TRAF6 degradation (Feng, 2005) . Thus, it is likely that TRAF6 interference using TRAF6C siRNA could also inhibit bone resorption in MM patients in addition to reducing myeloma tumor growth. IL-1 has also been implicated in MM-associated bone disease (reviewed by Callander and Roodman, 2001 ) and we have shown in this report that siTRAF6C effectively suppresses IL-1 signaling. Therefore, siTRAF6C may also reduce osteoclast activity in MM patients and, as a result, reduce bone loss and its associated skeletal complications which are the major clinical manifestations of myeloma.
The results of our in vitro and in vivo studies demonstrate for the first time the inhibition of myeloma cell proliferation and induction of tumor cell apoptosis with TRAF6 siRNA. These findings provide a better understanding of the role of TRAF6 in the growth of myeloma and offer a rationale to target this adapter protein for future therapeutic manipulation for patients with this B-cell malignancy. In all, 50-100 nM of siTRAF6C significantly inhibited MM proliferation whereas TRAF6Zn-finger or negative control GAPDH siRNAs had no effect. *Denotes statistically significant growth inhibition (*Po0.01). (b) Bone marrow mononuclear cells were isolated from two separate myeloma patients and cells transfected with 0-100 nM siTRAF6C or siGAPDH and assayed for proliferation as described above. SiTRAF6C significantly reduced MM cell viability in vitro. **Denotes statistically significant growth inhibition (**Po0.05).
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Materials and methods

siRNA design and construction
We generated two 21 bp human TRAF6 dsRNAs in vitro. The first RNAi oligo was complementary to the TRAF6Zn-finger mRNA nt 233-253 (sense 5 0 -AACCACAGCTGTTTTCACA GTCCTGTCTC*-3, antisense 5 0 -AAACTGTGAAAACAGC TGTGGCCTGTCTC*-3 0 ). The second RNAi oligo was complementary to the TRAF6C mRNA nt 420-440 (sense 5 0 -AAGCAGATGGGGCATTCATACCCTGTCTC-3 0 , antisense 5 0 -AAGTATGAATGCCCCATCTGCCCTGTCTC*-3 0 ). A third RNAi oligo to GAPDH (sense 5 0 -AAGGTGAAGGT CGGAGTCAACCCTGTCTC-3 0 , anti-sense 5 0 -AAGTTGAC TCCGACCTTCACCCCTGTCTC-3 0 was included as a negative control.
*CCCTGTCTC was complementary to the T7 promoter. No oligo was complementary to any other GenBank sequences. Small interfering RNA was generated and purified using a Silencer siRNA Construction Kit (Ambion, Austin, TX, USA as per manufacturer's directions).
Cell culture and generation of 8226/GFP stable transductants The myeloma cell line RPMI 8226 was obtained from the American Type Culture Collection (Manassas, VA, USA). RPMI media 8226 cells were transduced with a retroviral vector carrying pIRES-EGFP (BD Biosciences, San Diego, CA, USA). The transduced cells were sorted by FACS for expression of (GFP) and stable transductants (8226/GFP) selected by culture in 600 mg/ml Geneticin (Gibco, Carlsbad, CA, USA). TRAF6C siRNA inhibits myeloma cell growth H Chen et al serum (FBS) were aliquoted into 24-well culture plates and incubated overnight. On the following day, varying concentrations (25-100 nM) of siRNA in OPTI-MEM (Gibco) were added to each well with siPORT amine transfection agent (Ambion). After 24 h, 1 ml of fresh DMEM with 10% FBS without antibiotics was added to each well and cultured another 48 h.
Western blot analysis of TRAF protein expression Forty micrograms of 8226/GFP whole-cell lysates transfected with 50 or 100 nM siTRAF6C, and mock-transfected control cells, were electrophoresed on a 4-15% sodium dodecyl sulfate (SDS)-polyacrylamide gel. Proteins were transferred to polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA) and the membrane was blocked by incubating with 5% bovine serum albumin in tris-buffered saline (TBS) containing 0.5% Tween-20 (TBST) for 1 h at room temperature (RT). Blots were incubated with anti-TRAF2 (1:500, Medical and Biological Laboratories, Chicago, IL, USA), anti-TRAF5, anti-TRAF6 (both 1:500, eBioscience, San Diego, CA, USA). Protein expression was visualized using an enhanced chemiluminescence (ECL) detection system (Amersham Biosciences, Piscataway, NJ, USA). Protein expression was quantified using a Vesa-Doc gel documentation system (Bio-Rad).
Western blot analysis of NF-kB and AP-1 inhibition by siTRAF6C To determine optimal conditions, 8226/GFP cells were cultured in reduced-serum media containing 5%FBS for 24 h then stimulated with 20 ng/ml IL-1b (Sigma, St Louis, MO, USA) for 5-60 min. Stimulated cells were lysed with Laemmli buffer (50 mM tris, pH 6.8, 2% SDS and 10% glycerol containing protease inhibitors (1 mg/ml leupeptin, 1 mg/ml aprotinin and 2 mM phenylmethylsulfonyl fluoride, all from Sigma)) and 40 mg of whole cell lysates were separated by SDS-PAGE on a precast 4-20% tris-glycine gel (Invitrogen, Carlsbad, CA, USA). Proteins were transferred to Immobilon-NC nitrocellulose membranes (Millipore, Bilerica, MA, USA) and the membranes were blocked by incubating with 10% non-fat dry milk in TBST for 2 h at RT. Membranes were probed with anti-phospho-IkBa (S32), anti-phospho-NF-kB p65 (S536), anti-phospho-SEK1/MKK4 (S80), anti-phosphoc-Jun (S63/67), anti-IkBa, anti-NF-kB p65, anti-SEK1/ MKK4, anti-c-Jun (all 1:500, Cell Signaling Technology, Beverly, MA, USA) or anti-b actin-horse radish peroxidase (HRP) antibody (2 mg/ml, Sigma) antibodies were added and the protein blots were incubated for overnight at 41C. Membranes were washed with TBST three times for 5 min each followed by incubation with the appropriate HRPconjugated secondary antibody (KPL, Gaithersburg, MD, USA) diluted 1:500 in TBST at RT for 2 h. Membranes were washed as before and proteins detected using ECL Western Blotting Detection reagent (Amersham Biosciences, as per manufacturer's directions) and analysed using a FluorChem imaging system and Image J software (Alpha Innotech, San Leandro, CA, USA). Once the optimal conditions for IL-1b stimulation were determined, the 8226/GFP cells were cultured for 24 h in reduced serum media then transfected with siTRAF6C or siGAPDH as described above and incubated for an additional 48 h. Transfected cells were stimulated with 20 ng/ml IL-1b for 30 min, then the cell lysed and proteins analysed by Western blot as described above.
3-[4,5] Dimethylthiazol-2,5-diphenyltetrazolium bromide assay for cell proliferation 1 Â 10 4 stably 8226/GFP-transduced cells were transfected with 0, 50 or 100 nM TRAF6C, TRAF6Zn-finger or GAPDH siRNA, respectively, as described above. The transfected cells were incubated for 72 h and cell viability was determined using MTT assays as per manufacturer's directions (Sigma). Data represent the mean of experiments performed four times. Statistical significance was determined using the Student's t-test.
To introduce siRNA into fresh myeloma cells, mononuclear cells were first isolated from BM aspirates of two separate myeloma patients by centrifugation over a Histopaque 1077 (Sigma) density gradient. Bone marrow mononuclear cells containing >90% malignant cells were washed twice with phosphate-buffered saline and 1 Â 10 4 cells were resuspended in 100 ml Optimem (Gibco) and transfected with 0, 50 or 100 nM siTRAF6C or siGAPDH as described above. Transfected cells were incubated for 72 h and assayed for proliferation by MTT as described above.
Apoptosis analysis 8226/GFP or fresh MM cells were transfected with various concentrations of siRNA as before. Transfected cells were incubated for 48 h and apoptosis was measured by Annexin V and PPI staining as per manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN, USA) followed by flow cytometry (FC-500 cytometer using Cytomics CXP software, both Beckman-Coulter, Miami, FL, USA). As a positive control, cells were treated with 250 ng/ml of actinomycin D for 24 or 48 h. Each experiment was performed in triplicate and statistical significance determined using the Student's t-test.
In vivo cell survival assay Ten to 12-week-old (25-28 g) C57Bl/6J mice were irradiated with 750 cGy and the mice were divided into three groups of six mice each. The mice were injected with 1 Â 10 6 8226/GFP cells transfected with 100 nM siTRAF6C or siGAPDH into the BM of the left femur using a 27-gauge needle. A third group served as uninjected negative controls. After 1 week, the mice were killed and BM cells were harvested by flushing the medullary cavities with buffered Hanks solution using a 27-gauge needle. Bone marrow mononuclear cells (1 Â 10 7 ) were collected after hemolysis of red cells with hypotonic buffer (ammonium chloride buffer; BD Biosciences). To determine the 8226/GFP cell proliferation in the mouse BM, the cells were diluted to the desired concentration and analysed by flow cytometry.
